Lantheus Announces Share Repurchase Program
Lantheus Holdings (NASDAQ: LNTH) has announced a $250 million share repurchase program to be executed over the next twelve months. The company plans to begin repurchases in Q4 2023 through open market transactions, private negotiations, and other legal means, with timing and amounts determined by management based on market conditions. The program demonstrates the board's confidence in Lantheus' leadership in radiopharmaceuticals and growth potential. The company aims to balance capital return to shareholders while pursuing business development opportunities to expand its radiopharmaceutical portfolio.
Lantheus Holdings (NASDAQ: LNTH) ha annunciato un programma di riacquisto di azioni da 250 milioni di dollari che sarà eseguito nei prossimi dodici mesi. L'azienda prevede di iniziare i riacquisti nel quarto trimestre del 2023 attraverso transazioni di mercato aperto, negoziazioni private e altri mezzi legali, con tempistiche e importi determinati dalla direzione in base alle condizioni di mercato. Il programma dimostra la fiducia del consiglio nella leadership di Lantheus nei radiofarmaci e nel potenziale di crescita. L'azienda mira a bilanciare il ritorno di capitale agli azionisti mentre persegue opportunità di sviluppo aziendale per espandere il proprio portafoglio di radiofarmaci.
Lantheus Holdings (NASDAQ: LNTH) ha anunciado un programa de recompra de acciones de 250 millones de dólares que se llevará a cabo durante los próximos doce meses. La empresa planea iniciar las recompras en el cuarto trimestre de 2023 a través de transacciones en el mercado abierto, negociaciones privadas y otros medios legales, con los tiempos y montos determinados por la dirección según las condiciones del mercado. El programa demuestra la confianza del consejo en el liderazgo de Lantheus en radiofármacos y su potencial de crecimiento. La empresa busca equilibrar el retorno de capital a los accionistas mientras persigue oportunidades de desarrollo empresarial para expandir su cartera de radiofármacos.
Lantheus Holdings (NASDAQ: LNTH)는 향후 12개월 동안 실행될 2억 5천만 달러 규모의 자사주 매입 프로그램을 발표했습니다. 회사는 2023년 4분기부터 공개 시장 거래, 비공식 협상 및 기타 합법적인 방법을 통해 자사주 매입을 시작할 예정이며, 시기와 금액은 시장 조건에 따라 경영진의 판단에 따라 결정됩니다. 이 프로그램은 Lantheus의 방사선약물 분야에서의 리더십과 성장 잠재력에 대한 이사회의 신뢰를 보여줍니다. 회사는 방사선약물 포트폴리오를 확장하기 위한 사업 개발 기회를 추구하면서 주주에게 자본 반환을 균형 있게 하고자 합니다.
Lantheus Holdings (NASDAQ: LNTH) a annoncé un programme de rachat d'actions de 250 millions de dollars qui sera exécuté au cours des douze prochains mois. L'entreprise prévoit de commencer les rachats au quatrième trimestre 2023 par le biais de transactions sur le marché ouvert, d'accords privés et d'autres moyens légaux, les délais et montants étant déterminés par la direction en fonction des conditions du marché. Le programme démontre la confiance du conseil d'administration dans le leadership de Lantheus dans le domaine des radio-pharmaceutiques et son potentiel de croissance. L'entreprise vise à équilibrer le retour de capital aux actionnaires tout en poursuivant des opportunités de développement commercial pour élargir son portefeuille de radio-pharmaceutiques.
Lantheus Holdings (NASDAQ: LNTH) hat ein Aktienrückkaufprogramm im Wert von 250 Millionen Dollar angekündigt, das in den nächsten zwölf Monaten umgesetzt werden soll. Das Unternehmen plant, die Rückkäufe im 4. Quartal 2023 über den offenen Markt, private Verhandlungen und andere legale Mittel zu beginnen, wobei Zeitpunkt und Beträge von der Geschäftsführung basierend auf den Marktbedingungen bestimmt werden. Das Programm demonstriert das Vertrauen des Vorstands in die Führungsrolle von Lantheus im Bereich der Radiopharmazeutika und das Wachstumspotenzial. Das Unternehmen zielt darauf ab, die Rückgabe von Kapital an die Aktionäre mit der Verfolgung von Geschäftsentwicklungsmöglichkeiten in Einklang zu bringen, um sein Portfolio an Radiopharmazeutika zu erweitern.
- Authorization of $250 million share repurchase program
- Strong financial position enabling share buybacks
- Company maintains flexibility for business development alongside buybacks
- Potential reduction in cash available for operations and investments
- Share repurchase execution dependent on market conditions
Insights
The
The implementation of a potential 10b5-1 trading plan indicates a structured approach to buybacks, providing protection against insider trading concerns while ensuring systematic execution. The market typically views buybacks positively as they reduce share count, potentially increasing EPS and signaling management's confidence in the company's valuation and future prospects.
BEDFORD, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announces that its board of directors has authorized a program to repurchase up to
“With our strong financial position and the Board’s commitment to shareholder value, this share repurchase program reflects our confidence in Lantheus’ continued radiopharmaceuticals leadership and ability to drive long-term, sustainable growth,” said Brian Markison, Chief Executive Officer of Lantheus. “We intend to commence repurchases in the fourth quarter of this year and opportunistically return capital to shareholders over the next twelve months while simultaneously pursuing business development to expand our radiopharmaceutical portfolio.”
Such repurchases may be made from time to time through open market transactions at prevailing market prices, in privately negotiated transactions, and through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. The actual timing, number, and dollar amount of repurchase transactions will be determined by the Company’s management at its discretion and will depend on a number of factors including, but not limited to, the market price of the Company’s common stock. The Company may also establish 10b5-1 trading plans to provide flexibility if and when it buys back its common stock.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “believe,” “continue,” “could,” “guidance,” “may,” “plan,” “potential,” “predict,” “progress,” “should,” “target,” “will,” “would” and other similar terms. These forward-looking statements include the Company’s capital allocation plans, including the timing of any repurchases, and are subject to the risk and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).
Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Senior Director, External Communications
646-975-2533
media@lantheus.com
FAQ
How much is Lantheus' (LNTH) share repurchase program worth?
When will Lantheus (LNTH) start its share repurchase program?
How will Lantheus (LNTH) execute its share repurchase program?
